?????????????.??????????????????????????????????????Duvelisib was the second PI3K inhibitor approved from the FDA, also according to a phase III randomized trial.130 The efficacy and security profile from the drug seem comparable with People of idelalisib, Otherwise a little useful. Pertaining to alternate BTK inhibitors, there are various solution